‘Ridiculous at best’: Chinese state media give their take on Trump and the tariff war – CNBC
August 27, 2019China’s state media is putting up a brave front as the country’s trade war with the U.S. escalated sharply over the weekend.
Top China Trade Negotiator Calls for Calm as Trump Tensions Grow – Investing.com
August 27, 2019On August 26, Amgen (AMGN) announced the purchase of leading immunology drug Otezla from Celgene (CELG) for a cash consideration of $13.4 billion.
Democrats need a China strategy to replace Trump’s aggressive policy – Nikkei Asian Review
August 27, 2019US must unite at home before it can realistically face up to Beijing
Top China Trade Negotiator Calls for Calm as Trump Tensions Grow – Investing.com
August 27, 2019VMware debuted its Tanzu and Project Pacific products so coders can build and run Kubernetes-powered apps.
Amgen and Celgene’s Otezla Deal: Key Highlights – Market Realist
August 27, 2019On August 26, Amgen (AMGN) announced the purchase of leading immunology drug Otezla from Celgene (CELG) for a cash consideration of $13.4 billion.
Imagine Siri as your IT help desk. Too scary? OK, imagine PAYG on-prem IT. Oh, too much? How about everything on Kubernetes? – The Register
August 27, 2019Wait, come back. Stop screaming. We’re only reading out VMware’s news
Popeyes’ chicken sandwich is surprise hit: ‘We didn’t expect this type of reaction’ – Fox News
August 27, 2019Apparently, people really wanted a new chicken sandwich.
Trump’s company could save millions if interest rates fall like he wants – AOL
August 27, 2019President Donald Trump would save millions in annual interest payments if the Fed interest rates fall.
Amgen, maker of Enbrel, to pick up Celgene’s Otezla for $13.4B. Will FTC hit back? – FiercePharma
August 26, 2019Looks like Amgen might not be buying Alexion after all. Instead, it’s beefing up in psoriasis, where it already sells blockbuster TNF inhibitor Enbrel, by snatching up Celgene’s Otezla for $13.4 billion.
Amgen Will Buy Celgene Drug in $13.4 Billion Antitrust Sale – Yahoo Finance
August 26, 2019(Bloomberg) — Amgen Inc. will pay $13.4 billion for a blockbuster psoriasis drug from Celgene Corp., which is shedding the asset in order to win antitrust regulators’ sign-off for its $74 billion merger with Bristol-Myers Squibb Co.The all-cash deal will give Amgen a growing product at a time when the
